Monday, August 20, 2007 6:49:38 PM
Zhemian Ventures told me that Appletree Capital/WNSH already has a list of confirmed Institutional clientele for support. I was also told that Appletree Capital/WNSH and any company dealing with them are debt free and profitable. Also, others have emails from the CEO stating that WNSH is debt free. This means that any of the Revenues from the $125 million deal (The Carry and The Management Fee) will instantly be considered as Earnings/Profits. Let’s now determine the Revenues from “The Carry and The Management Fee” from the percentages I derived from the post below:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=22223641
Revenues from the Carry:
Below reflects the 20% conservative return for “The Carry” from the $125 million deal:
$125,000,000 x .20 = $25,000,000
Revenues from “The Carry” = $25,000,000
Revenues from the Management Fee:
Below reflects the 2% minimum return for “The Management Fee” from the $125 million deal:
$125,000,000 x .02 = $2,500,000
Revenues from the Management Fee = $2,500,000
Total Revenues from the Carry & the Management Fee:
The total amount that Appletree Capital would walk away with from this $125,000,000 deal from both “The Carry” and “The Management Fee” would be:
$25,000,000 + $2,500,000 = $27,500,000
Since Appletree Capital is debt free with “zero” Expenses, the $27,500,000 million in Revenues would be considered Earnings/Profits. Since…
Revenues – Expenses = Earnings/Profits
$27,500,000 - $0 = Earnings/Profits
$27,500,000 = Earnings/Profits
The 3rd question to now answer is…
3. What is a conservative Earnings Per Share (EPS) for Appletree Capital/WNSH “IF” the $125 million deal is completed given the Earnings/Profits revealed above and an Outstanding Shares (OS) structure of 3,620,241,722 shares?
If no major and/or constructive disagreement is made, I will continue on.
v/r
Sterling
Sterling's Trading & Investing Strategies:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29867262
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM